MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,health report with the FDA on 2020-03-30 for JUVEDERM VOLLURE XC 2X1 ML 95661 manufactured by Allergan (pringy).
Report Number | 3005113652-2020-00141 |
MDR Report Key | 9900525 |
Report Source | COMPANY REPRESENTATIVE,HEALTH |
Date Received | 2020-03-30 |
Date of Report | 2020-03-30 |
Date of Event | 2020-02-10 |
Date Mfgr Received | 2020-03-02 |
Date Added to Maude | 2020-03-30 |
Event Key | 0 |
Report Source Code | Manufacturer report |
Manufacturer Link | Y |
Number of Patients in Event | 0 |
Adverse Event Flag | 3 |
Product Problem Flag | 3 |
Reprocessed and Reused Flag | 3 |
Reporter Occupation | PHYSICIAN ASSISTANT |
Health Professional | 3 |
Initial Report to FDA | 3 |
Report to FDA | 3 |
Event Location | 3 |
Manufacturer Contact | MRS. MICHELLE BURGESS |
Manufacturer Street | 12331-A RIATA TRACE PARKWAY BUILDING 3 |
Manufacturer City | AUSTIN TX 78727 |
Manufacturer Country | US |
Manufacturer Postal | 78727 |
Manufacturer Phone | 7372473605 |
Manufacturer G1 | ALLERGAN (PRINGY) |
Manufacturer Street | ROUTE DE PROMERY ZONE ARTISANALE DE PRE-MAIRY |
Manufacturer City | PRINGY 74370 |
Manufacturer Country | FR |
Manufacturer Postal Code | 74370 |
Single Use | 0 |
Previous Use Code | 0 |
Event Type | 3 |
Type of Report | 3 |
Brand Name | JUVEDERM VOLLURE XC 2X1 ML |
Generic Name | IMPLANT, DERMAL, FOR AESTHETIC USE |
Product Code | LMH |
Date Received | 2020-03-30 |
Catalog Number | 95661 |
Lot Number | V17LA90016 |
Operator | HEALTH PROFESSIONAL |
Device Availability | N |
Device Sequence No | 1 |
Device Event Key | 0 |
Manufacturer | ALLERGAN (PRINGY) |
Manufacturer Address | ROUTE DE PROMERY ZONE ARTISANALE DE PRE-MAIRY PRINGY 74370 FR 74370 |
Brand Name | HYDROCHLORIDE LIDOCAINE / 0.3 % |
Product Code | --- |
Date Received | 2020-03-30 |
Device Sequence No | 101 |
Device Event Key | 0 |
Patient Number | Treatment | Outcome | Date |
---|---|---|---|
1 | 0 | 1. Required No Informationntervention | 2020-03-30 |